RBRC01869, B6.129-Nod2<tm1Jhgt>

RBRC No. RBRC01869
Type Targeted MutationCartagena
Species Mus musculus
Strain name B6.129-Nod2<tm1Jhgt>
Former Common name Card15 KO (C57BL/6N background)
H-2 Haplotype No Data
Background strain No Data
Appearance
1 Appearance No Data
Genotype No Data
Strain development Developed by Marco Giovannini, INSERM. PGK-hygromycin cassette was removed by cre recombinase.
Strain description This mouse was produced from the knock-in targeting of Card15 (Nod2) locus with EGFP cassette. The expression of the GFP is relatively low. C57BL/6 congenic (RBRC01869), C57BL/6 and 129 mixed background (RBRC01941).
Colony maintenance Homozygote x Homozygote
Health Report
Gene Details
Promoter No Data
1 Symbol Nod2
Symbol name caspase recruitment domain family, member 15
Chromosome 8
Common name F830032C23Rik, IBD1, Nod2
Symbol description No Data
2 Symbol EGFP
Symbol name Enhanced Green Fluorescent Protein, F64L and S65T (Jellyfish)
Chromosome 8
Common name No Data
Symbol description No Data
3 Symbol loxP
Symbol name phage P1 loxP
Chromosome 8
Common name No Data
Symbol description No Data
References

Research applications Cre/loxP system,
Fluorescent Proteins/lacZ System,
Immunology and Inflammation Research,
Internal/Organ Research,
Mouse Models for Human Disease
Specific Term and Conditions The following terms and conditions will be requested by the DEPOSITOR.
In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
RECIPIENT shall keep DEPOSITOR apprised of any results obtained from the BIOLOGICAL RESOURCE in the course of the research, as soon as they are available. Moreover, if the research results in a potential invention or a substance that may have potential commercial value (hereinafter referred as to the “Invention”) RECIPIENT will promptly disclose this Invention to DEPOSITOR with samples thereof for DEPOSITOR’s internal use.
RECIPIENT and DEPOSITOR will consult together and agree about the possibility of filing one or more patent application to Invention conceived by one or more employees of Recipients that directly arise out of the research. The Parties will negotiate in good faith the conditions of such patent application according to each party’s inventiveness contribution in the Invention.
In case of such Invention, patentable or not, reduced in practice or developed in the course of the research that could not have been obtained, reduced to practice or developed but from using the Material and/or Confidential Information, RECIPIENT and DEPOSITOR shall confer with one another as regards licensing and commercialization of such Invention to negotiate in good faith the terms of an institutional agreement as regards said matters.
Additional information
1 GFP Transfer License (Japanese / English)
Please fill in the Schedule A, and submit two signed copies to us together with two signed copies of RIKEN BRC’s MTA. Please also read Schedule B.
2 Mouse of the Month Jun 2007
3 Genotyping protocol <PCR>
Depositor Giovannini, Marco (House Ear Institute) Giovannini, Marco
Strain Status /
Availability
(Expected delivery)


Frozen
Cryopreserved embryos : Within 1 month
Recovered litters from cryopreserved embryos : 2-4 months
BRC mice in Publications
Title Journal
(PMID)
Author
NOD2 deletion promotes cardiac hypertrophy and fibrosis induced by pressure overload. Lab Invest.93(10): 1128-36 (2013).(23958879)
Zong J, Salim M, Zhou H, Bian ZY, Dai J, Yuan Y, Deng W, Zhang JY, Zhang R, Wu QQ, Tang QZ.

RBRC01870, FVB.Cg-Nf2<tm1Gvn>/GvnRbrc

RBRC No. RBRC01870
Type Targeted MutationCartagena wks
Species Mus musculus
Strain name FVB.Cg-Nf2<tm1Gvn>/GvnRbrc
Former Common name Nf2 iso1 KO
H-2 Haplotype No Data
Background strain No Data
Appearance
1 Appearance albino
Genotype A/A B/B c/c D/D P/P
Strain development Developed by Dr. Marco Giovannini, INSERM France.
Strain description Nf2 isoform 1 knock-out mice. Nf2, Neurofiboromatosis type 2 is a tumor suppressor gene encoding a putative cytoskeletal asssociated protein. Homozygous mutant mice are viable and fertile.
Colony maintenance Homozygote x Homozygote
Health Report
Gene Details
Promoter No Data
1 Symbol Nf2
Symbol name neurofibromatosis 2
Chromosome 11
Common name merlin, moesin-ezrin-radixin-like protein, schwannomin
Symbol description No Data
2 Symbol loxP
Symbol name phage P1 loxP
Chromosome 11
Common name No Data
Symbol description No Data
References No Data

Research applications No Data
Specific Term and Conditions The following terms and conditions will be requested by the DEPOSITOR.
In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
RECIPIENT shall keep DEPOSITOR apprised of any results obtained from the BIOLOGICAL RESOURCE in the course of the research, as soon as they are available. Moreover, if the research results in a potential invention or a substance that may have potential commercial value (hereinafter referred as to the “Invention”) RECIPIENT will promptly disclose this Invention to DEPOSITOR with samples thereof for DEPOSITOR’s internal use.
RECIPIENT and DEPOSITOR will consult together and agree about the possibility of filing one or more patent application to Invention conceived by one or more employees of Recipients that directly arise out of the research. The Parties will negotiate in good faith the conditions of such patent application according to each party’s inventiveness contribution in the Invention.
In case of such Invention, patentable or not, reduced in practice or developed in the course of the research that could not have been obtained, reduced to practice or developed but from using the Material and/or Confidential Information, RECIPIENT and DEPOSITOR shall confer with one another as regards licensing and commercialization of such Invention to negotiate in good faith the terms of an institutional agreement as regards said matters.
Additional information
1 No Data
2 Genotyping protocol <PCR>
Depositor Giovannini, Marco (House Ear Institute) Giovannini, Marco
Strain Status /
Availability
(Expected delivery)


Frozen
Cryopreserved embryos : Within 1 month
Recovered litters from cryopreserved embryos : 2-4 months

Sperm
Cryopreserved sperm : Within 1 month
Recovered litters from cryopreserved sperm : 2-4 months

RBRC01871, FVB.Cg-Nf2<tm2Gvn>/GvnRbrc

RBRC No. RBRC01871
Type Targeted MutationCartagena
Species Mus musculus
Strain name FVB.Cg-Nf2<tm2Gvn>/GvnRbrc
Former Common name Nf2 iso2 KO
H-2 Haplotype No Data
Background strain No Data
Appearance
1 Appearance No Data
Genotype No Data
Strain development Developed by Dr. Marco Giovannini, INSERM France.
Strain description Nf2, Neurofiboromatosis type 2 is a tumor suppressor gene encoding a putative cytoskeletal asssociated protein.
Colony maintenance Sibling Mating (Homozygote x Homozygote)
Health Report
Gene Details
Promoter No Data
1 Symbol Nf2
Symbol name neurofibromatosis 2
Chromosome 11
Common name merlin, moesin-ezrin-radixin-like protein, schwannomin
Symbol description No Data
2 Symbol loxP
Symbol name phage P1 loxP
Chromosome 11
Common name No Data
Symbol description No Data
References No Data

Research applications Cancer Research,
Cell Biology Research,
Cre/loxP system
Specific Term and Conditions The following terms and conditions will be requested by the DEPOSITOR.
In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
RECIPIENT shall keep DEPOSITOR apprised of any results obtained from the BIOLOGICAL RESOURCE in the course of the research, as soon as they are available. Moreover, if the research results in a potential invention or a substance that may have potential commercial value (hereinafter referred as to the “Invention”) RECIPIENT will promptly disclose this Invention to DEPOSITOR with samples thereof for DEPOSITOR’s internal use.
RECIPIENT and DEPOSITOR will consult together and agree about the possibility of filing one or more patent application to Invention conceived by one or more employees of Recipients that directly arise out of the research. The Parties will negotiate in good faith the conditions of such patent application according to each party’s inventiveness contribution in the Invention.
In case of such Invention, patentable or not, reduced in practice or developed in the course of the research that could not have been obtained, reduced to practice or developed but from using the Material and/or Confidential Information, RECIPIENT and DEPOSITOR shall confer with one another as regards licensing and commercialization of such Invention to negotiate in good faith the terms of an institutional agreement as regards said matters.
Additional information
1 No Data
Depositor Giovannini, Marco (House Ear Institute) Giovannini, Marco
Strain Status /
Availability
(Expected delivery)


Frozen
Cryopreserved embryos : Within 1 month
Recovered litters from cryopreserved embryos : 2-4 months

Sperm
Cryopreserved sperm : Within 1 month
Recovered litters from cryopreserved sperm : 2-4 months

RBRC01872, ApcFlox14

RBRC No. RBRC01872
Type Targeted MutationCartagena wks
Species Mus musculus
Strain name ApcFlox14
Former Common name No Data
H-2 Haplotype No Data
Background strain No Data
Appearance
1 Appearance albino
Genotype A/A B/B c/c D/D P/P
Strain development Developed by Dr. Marco Giovannini, INSRM France. FVB/N background.
Strain description FVB.Cg-Apc<tm2.1Cip>. Apc, adenomatosis polyposis coli is a member of the Wnt signaling pathway that is involved in development and tumorigenesis. This conditional knockout mice have a loxP-flanked Apc allele. Conditional Apc deficient mice can be generated by crossing with tissue-specific Cre mice.
Colony maintenance Sibling Mating
Health Report
Gene Details
Promoter No Data
1 Symbol Apc
Symbol name adenomatosis polyposis coli
Chromosome 18
Common name No Data
Symbol description No Data
2 Symbol loxP
Symbol name phage P1 loxP
Chromosome 18
Common name No Data
Symbol description No Data
References No Data

Research applications Cre/loxP system
Specific Term and Conditions The following terms and conditions will be requested by the DEPOSITOR.
In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested.
Proc. Natl. Acad. Sci., 101, 17216-17221 (2004). Lab Invest., 84, 1619-1930 (2004).
In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
RECIPIENT shall keep DEPOSITOR apprised of any results obtained from the BIOLOGICAL RESOURCE in the course of the research, as soon as they are available. Moreover, if the research results in a potential invention or a substance that may have potential commercial value (hereinafter referred as to the “Invention”) RECIPIENT will promptly disclose this Invention to DEPOSITOR with samples thereof for DEPOSITOR’s internal use.
RECIPIENT and DEPOSITOR will consult together and agree about the possibility of filing one or more patent application to Invention conceived by one or more employees of Recipients that directly arise out of the research. The Parties will negotiate in good faith the conditions of such patent application according to each party’s inventiveness contribution in the Invention.
In case of such Invention, patentable or not, reduced in practice or developed in the course of the research that could not have been obtained, reduced to practice or developed but from using the Material and/or Confidential Information, RECIPIENT and DEPOSITOR shall confer with one another as regards licensing and commercialization of such Invention to negotiate in good faith the terms of an institutional agreement as regards said matters.
Additional information
1 No Data
2 Genotyping protocol <PCR>
Depositor Giovannini, Marco (House Ear Institute) Giovannini, Marco
Strain Status /
Availability
(Expected delivery)


Frozen
Cryopreserved embryos : Within 1 month
Recovered litters from cryopreserved embryos : 2-4 months
BRC mice in Publications
Title Journal
(PMID)
Author
Contribution of ATOH1+ Cells to the Homeostasis, Repair, and Tumorigenesis of the Colonic Epithelium. Stem Cell Reports (2017).(29233556)
Ishibashi F, Shimizu H, Nakata T, Fujii S, Suzuki K, Kawamoto A, Anzai S, Kuno R, Nagata S, Ito G, Murano T, Mizutani T, Oshima S, Tsuchiya K, Nakamura T, Watanabe M, Okamoto R.